## ABVX: ABIVAX Société Anonyme - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 6.6% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops. Caution: momentum weakening (-4.4% MRS).

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($122.18)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Guggenheim Securities has assigned a 'Buy' rating to Abivax, citing optimism about the prospects of its core drug, obefazimod.**
- Source: 富途牛牛 | 20251229T120942 | Bullish | Relevance: 100%
- Guggenheim Securities has initiated a 'Buy' rating for Abivax (ABVX.US), increasing its target price to $175 from $150, based on promising prospects for its core drug, obefazimod. The French biotechnology company's stock rose over 5% in pre-market trading following the news. Abivax is anticipating key data readouts in early 2026 for its ABTECT maintenance trial and plans to submit a New Drug Application to the U.S. FDA in the latter half of 2026.

**2. 61,449 Shares in Abivax SA Sponsored ADR $ABVX Purchased by Simplify Asset Management Inc.**
- Source: MarketBeat | 20251230T133522 | Neutral | Relevance: 100%
- Simplify Asset Management Inc. recently acquired 61,449 shares of Abivax SA Sponsored ADR ($ABVX), valued at approximately $5.217 million, bringing its ownership to about 0.08%. Institutional investors and hedge funds collectively own 47.91% of the company. Despite analysts' consensus "Moderate Buy" rating with a target price of $128.73, the stock is currently trading near $140.40 with a market capitalization of $10.94 billion and last reported a negative EPS of ($2.46).

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | Citizens | $131 | $114 | +15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | Citizens | main | Market Outperform |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 34.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- TCG Crossover Manage: 9.1% (+17.4%)
- UBS Group AG: 5.7% (+2561.0%)
- Darwin Global Manage: 4.1% (+100.0%)
- Point72 Asset Manage: 3.8% (+1642.4%)
- Cormorant Asset Mana: 2.5% (-8.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Balance sheet: strong liquidity (7.9x), low leverage (D/E 0.28). Revenue growth strong at 605% YoY. Analyst sentiment positive (1 raises, avg +15%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.9B |
| Beta | -0.11 |
| 52W Range | $4.77 - $148.83 |
| Short Interest | 3.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 11.0% to 6.6% (-4.4% in 5 days), indicating relative weakness vs NASDAQ. Extended beyond STRENGTH zone (6.6% > 6.0%), caution on chasing. MRS_5 (-1.4%) diverging from MRS_10 - short-term weakness emerging. Outperforming sector by 5.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.65), confirming momentum. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 6.59% (CS: 99) | Strong |
| RSI_14 | 62.3 | Neutral |
| MACD Histogram | 1.65 | Bullish |
| vs SMA20 | 1.113x | Above |
| vs SMA50 | 1.218x | Above |
| vs SMA200 | 2.459x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $138.34
- **Stop Loss:** $122.18 (11.7% risk)
- **Target:** $154.50 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 81
- **Position Value:** $11,205.54
- **Portfolio %:** 11.21%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-03-23 (Est: $0.00)

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*